Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy

Gut

Volumn 55, Issue 11, 2006, Pages 1631-1638

  Sherman, M ^a   Yoshida, E M ^b   Deschenes, M ^c   Krajden, M ^d   Bain, V G ^e   Peltekian, K ^f   Anderson, F ^g   Kaita, K ^h   Simonyi, S ⁱ   Balshaw, R ^j   Lee, S S ^k  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g Liver and Intestinal Research Centre   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ Roche   (Canada)

^j Syreon Corporation   (Canada)

^k UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ANEMIA; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VIROLOGY; VIRUS INFECTION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PATIENT DROPOUTS; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33750369259     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.083113     Document Type: Article

References (25)

1. National Institutes of Health. Consensus Development Conference Statement: Management of hepatitis C: 2002. June 10-12, 2002. Hepotology 2002;36:S3-20.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
6. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for me treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
7. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19(suppl 1):57-65.
8. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
9. EASL International Consensus Conference on Hepatitis C. Paris, 20-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956-61.
10. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002;36:S128-34.
11. Veldt BJ, Brouwer JT, Adler M, et al. Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with ribavirin and interferon in 121 patients in me Benelux [ISRCTN53821378]. BMC Gastroenterol 2003;3:24.
12. Poynard T, Marcellin P, Bissery A, et al. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. J Viral Hepat 2003;10:197-204.
13. Lim JK, Imperial JC, Keeffe EB. Retreatment of chronic hepatitis C virus infection. Rev Gastroenterol Disord 2004;4:97-103.
14. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
15. Krawitt EL, Ashikaga T, Gordon SR, et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005;43:243-9.
16. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 2001;79:373-4.
17. Lee SS, Bain VG, Peltekian K, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006;23:397-408.
18. Chousterman M, Auray-Cartier V, Hagege H, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or standard combination therapy. Hepatology 2002;36:362A.
19. Diago M, Romero-Gomez M, Crespo J, et al. Peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: final results of the Spanish high-dose induction pilot trial. Hepatology 2004;40(suppl 1):389A.
20. Rodriguez Torres M, Rodriguez Orengo J. Efficacy of PEG-IFN-alfa-2a (PEGASYS) vs Pegasys and RBV for HIV/HCV coinfected patients that are nonresponders to previous IFN therapy. Hepatology 2003;38(suppl 1):325A.
21. Taliani G, Aceti A, Caponni M, et al. Pegylated interferon alpha-2b plus ribavirin in the re-treatment of patients non responsive to IFN/ribavirin. J Hepatol 2005;42(suppl 2):222.
22. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
23. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
24. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patient: with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370-81.
25. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002;36:S185-94.